Overweight Clinical Trials in Dallas, Texas

16 studies are recruiting for overweight in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

    The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    Fortrea Clinical Research Unit - Dallas, Dallas, Texas
    Locations
    9 in total
    Run by
    Amgen

    See if you can join NCT07908316 on ClinicalTrials.gov

  2. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

    Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Velocity Clinical Research - Dallas /ID# 282734, Dallas, Texas
    Locations
    64 in total
    Run by
    AbbVie

    See if you can join NCT07752979 on ClinicalTrials.gov

  3. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Velocity Clinical Research, Dallas, Dallas, Texas
    Locations
    143 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07282600 on ClinicalTrials.gov

  4. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    FutureSearch Trials of Dallas, Dallas, Texas
    Locations
    40 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov

  5. A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

    This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cedar Health Research - Texas Native Health, Dallas, Texas
    Locations
    180 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07794579 on ClinicalTrials.gov

  6. A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

    The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), …

    Stage
    Phase 1
    Ages
    18 to 60
    Site
    Fortrea Clinical Research Unit, Dallas, Texas
    Locations
    2 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07808060 on ClinicalTrials.gov

  7. A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

    The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participa…

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    Fortrea Clinical Research Unit, Dallas, Texas
    Locations
    3 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07808073 on ClinicalTrials.gov

  8. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Velocity Clinical Research, Dallas, Dallas, Texas
    Locations
    57 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06143956 on ClinicalTrials.gov

  9. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Cedar Health Research, LLC, Dallas, Texas
    Locations
    92 in total
    Run by
    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

  10. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UT Southwestern Med Center, Dallas, Texas
    Locations
    74 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07533175 on ClinicalTrials.gov

  11. A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UT Southwestern Med Center, Dallas, Texas
    Locations
    45 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07668414 on ClinicalTrials.gov

  12. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (trea…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    North Texas Endocrine Center, Dallas, Texas
    Locations
    41 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07720271 on ClinicalTrials.gov

  13. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Velocity Clinical Research, Dallas, Dallas, Texas
    Locations
    158 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07321886 on ClinicalTrials.gov

  14. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Locations
    185 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07392190 on ClinicalTrials.gov

  15. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cedar Health Research, Dallas, Texas
    Locations
    62 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07770841 on ClinicalTrials.gov

  16. AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mercy Family Clinic, Dallas, Texas
    Locations
    81 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07509307 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.